|
邓渊尹.中国嵌合抗原受体T细胞治疗恶性血液病临床研究进展[J].内科急危重症杂志,2025,31(2):102-107
|
| DOI：10.11768/nkjwzzzz20250202 |
| 中文关键词: 嵌合抗原受体T细胞疗法 功能增强型 新靶点 通用型 序贯治疗 |
| 英文关键词: |
| 基金项目:国家自然科学基金(82270234;82425002;82341206);浙江省尖兵领雁攻关研究计划(2023C03060) |
|
| 摘要点击次数: 78 |
| 全文下载次数: 126 |
| 中文摘要: |
| 摘要 嵌合抗原受体T（CAR-T）细胞疗法是一种新兴的细胞免疫治疗手段。近年来，该疗法在治疗复发难治性B细胞来源的恶性血液病方面展现出显著成效。本综述回顾了我国CAR-T细胞治疗的发展历程，重点介绍了功能增强型、双靶点、新靶点和通用型等新型CAR-T细胞研发及临床转化进展。同时，深入探讨多种临床研究方案，以期为未来的研究和临床实践提供新的思路与方向。 |
| 英文摘要: |
| Abstract Chimeric antigen receptor-T (CAR-T) cell therapy represents an innovative form of cellular immunotherapy. In recent years, this therapeutic approach has shown remarkable efficacy in treating relapsed and refractory B-cell-derived hematological malignancies. This review summarizes the evolution of CAR-T cell therapy in China, emphasizing advancements in novel CAR-T cells, including functionally enhanced, dual-targeted, new-targeted, and universal CAR-T cells. Additionally, it explores various innovative treatment regimens in clinical applications, aiming to provide new perspectives and directions for future research and clinical practice. |
|
